|
Slemmon, J R; Wengenack, T M; Flood, D G (1997) Profiling of endogenous peptides as a tool for studying development and neurological disease. Biopolymers 43:157-70
|
|
Kazee, A M; Cox, C; Richfield, E K (1995) Substantia nigra lesions in Alzheimer disease and normal aging. Alzheimer Dis Assoc Disord 9:61-7
|
|
Maguire-Zeiss, K A; Li, Z W; Shimoda, L M et al. (1995) Calbindin D28k mRNA in hippocampus, superior temporal gyrus and cerebellum: comparison between control and Alzheimer disease subjects. Brain Res Mol Brain Res 30:362-6
|
|
Wetzel, D M; Bohn, M C; Kazee, A M et al. (1995) Glucocorticoid receptor mRNA in Alzheimer's diseased hippocampus. Brain Res 679:72-81
|
|
Flood, D G (1994) Thoughts on no neocortical neuronal loss but loss of volume in AD. Neurobiol Aging 15:363-5;discussion 379-80
|
|
Slemmon, J R; Hughes, C M; Campbell, G A et al. (1994) Increased levels of hemoglobin-derived and other peptides in Alzheimer's disease cerebellum. J Neurosci 14:2225-35
|
|
Wetzel, D M; Bohn, M C; Hamill, R W (1994) Postmortem stability of mRNA for glucocorticoid and mineralocorticoid receptor in rodent brain. Brain Res 649:117-21
|
|
Jette, N; Cole, M S; Fahnestock, M (1994) NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Brain Res Mol Brain Res 25:242-50
|
|
Benesch, C G; McDaniel, K D; Cox, C et al. (1993) End-stage Alzheimer's disease. Glasgow Coma Scale and the neurologic examination. Arch Neurol 50:1309-15
|
|
Kazee, A M; Eskin, T A; Lapham, L W et al. (1993) Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis Assoc Disord 7:152-64
|
Showing the most recent 10 out of 38 publications
